Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Why & What of the ACR’s Clinical Practice Guidelines

Ruth Jessen Hickman, MD  |  Issue: February 2018  |  February 18, 2018

Dr. Caplan thinks it is a mistake to conclude that lack of level A evidence on a given question should imply that guidelines are not desirable and should notIdeally, the process of guideline formation itself could be used to help shape the research agenda, & guidelines do usually contain recommendations for future research. be attempted. “That’s philosophically at odds with feedback we’ve gotten from the ACR membership. Rheumatologists and healthcare practitioners in rheumatology want guidance from experts, specifically in areas in which there isn’t clear evidence. That is the mandate of the membership and, therefore, ACR leadership. It’s the decision of the ACR to offer that kind of guidance, but to be clear and transparent about the evidence base for that.”

He notes that the ACR offers that guidance with the explicit statement that the recommendations are not as supported as would be ideal, but they are the best possible guidelines given the available evidence.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Caplan points out that potential guidelines based only on level A evidence would likely address only issues that are agreed upon and obvious to everyone. “The benefit of articulating those common sense and generally universally regarded principles may not be as useful to clinicians.” He adds, “What is difficult is getting guidance for areas for which there isn’t clear evidence and having a logic at least underlying your actions. To apply a system that requires level A evidence to every decision is not an approach that recognizes the reality of medical practice or the differences in certain subspecialties vs. general care.”

Dr. Neogi also defends the use of imperfect non-level A data in the creation of clinical guidelines.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“We have to help our rheumatology colleagues and the broader community taking care of millions of patients with rheumatic diseases; we need to be able to help them optimally manage patients they are seeing in their practices now.” In her view, in the absence of RCT data, the ACR still needs to be able to provide useful information based on the best available data to date, while being transparent about the fact the particular recommendations are not based on RCT data. She adds, “Otherwise, we’re doing millions of patients and providers a disservice by not addressing clinically important questions.”

Although RCTs can be considered the gold standard, both Dr. Caplan and Dr. Neogi believe it is possible to overstate their importance. Dr. Neogi points out that with current improved epidemiological methods, data from well-done observational studies can be more reliable than in the past. In response to the claim that the ACR’s recommendations are “mostly expert based,” Dr. Caplan responds that to some extent, all guidelines are expert based. “There is always extrapolation, and there are always experts contributing to this process.”

Page: 1 2 3 4 5 6 7 8 9 10 | Single Page
Share: 

Filed under:Practice Support Tagged with:Clinical Practice GuidelinesThe American College of Rheumatology

Related Articles
    Dr. Caplan turned 106 on Nov. 21 and remains physically and mentally active.

    Paul S. Caplan, MD: A Physician’s Journey

    March 8, 2020

    Editor’s note: It is with much sadness that we learned this morning that Paul Caplan, MD, passed away yesterday, March 7, 2020. “He was a remarkable person who continued to celebrate life up to the end,” says Terence W. Starz, MD, University of Pittsburgh School of Medicine. “He had a great caring, wisdom, and commitment…

    Alisusha; Trueffelpix / shutterstock.com

    3 New Vasculitis Guidelines Discussed

    May 13, 2021

    The ACR, in concert with the Vasculitis Foundation, released three new vasculitis guidelines online first in July, with a fourth slated for publication by the end of the year. These are the first ever to be produced and endorsed by the ACR and the Vasculitis Foundation. Although most of the recommendations are conditional, due to…

    Vasculitis Guidelines in Focus, Part 6: Giant Cell Arteritis

    September 27, 2022

    In 2021, the ACR—in concert with the Vasculitis Foundation (VF)—released four new vasculitis guidelines, one each on: 1) anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, 2) giant cell arteritis (GCA) and Takayasu arteritis, 3) polyarteritis nodosa and 4) Kawasaki disease. The guideline development process is complex. For the vasculitis guidelines, this process kicked off in June…

    Updated Perioperative Guideline Released: Recommendations Balance Risks of Infection & Disease Flare

    September 13, 2022

    The 2017 recommendations are updated to reflect changes in medical literature, as well as to include newly approved drugs.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences